Fycompa, which was discovered and developed in the UK and Japan, was first launched globally in the UK on 12 September 2012.
The production of the drug will take place at Eisai’s European, Middle-East, Africa (EMEA) and Russia headquarters, situated in Hatfield, UK.
The £100m investment is part of comprehensive neurosciences research and development (R&D) programme, which focuses on illnesses affecting the brain such as dementia and epilepsy.
The investment is also expected to increase company’s product discovery, packaging and supply infrastructure and also trigger a partnership initiatives between the NHS, UK academic institutions and commercial partners.
Eisai EMEA and Russia president and CEO Gary Hendler said manufacturing Fycompa in Hatfield bucks a general trend of decline for pharmaceutical manufacturing in UK.
”If we want to reverse this trend there is an increasing need for the NHS to embrace these new therapies, encouraging better patient outcomes, and faster uptake of new medicines,” Hendler added.
England Minister for Universities and Science Rt Hon David Willetts said, "New investments of this nature greatly improve discovery, development and uptake of innovative new medicines in the UK, bringing benefits for patients and driving long-term, sustainable growth."
Fycompa sales are expected to be more than $500m by 2015, according to the company.